



# SAFETY DATA SHEET

Revision date 15-Jun-2025

Version 6

Page 1 / 19

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Methyprednisolone Acetate Injectable Suspension, Single-Dose Vial

**Product Code(s)** PZ01044

**Synonyms** PNU-8210

**Trade Name:** DEPO-MEDROL; DEPO-NISOLONE; DEPO-MEDRONE; DEPO-MODERIN; DEPO-MEDOL; DEPO-MEDRATE

**Item Code** H000400470, H000401047, H000401048, H000401071, H000401072, H000401073, H000401074, H000401105, H000420001, H000420005, H000011490, H000011491, H000011873, H000011874, H000401242, H000401243, H000020331, H000020536, H000402477, H000402479, H000402968, H000402474

**Chemical Family:** Glucocorticoid

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as anti-inflammatory

### 1.3. Details of the supplier of the safety data sheet

Pfizer Inc  
66 Hudson Boulevard East  
New York, New York 10001  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** CHEMTREC (24 hours): 1-800-424-9300

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

**Reproductive toxicity**

Category 1A - (H360D)

**Specific target organ toxicity (repeated exposure)**

Category 2 - (H373)

**Hazardous to the aquatic environment - chronic**

Category 2 - (H411)

### OSHA Classification

**Hazards not otherwise classified (HNOC)**

Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**

Not applicable

### 2.2. Label elements

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 2 / 19

Version 6



## Signal word

## Hazard statements

Danger

H360D - May damage the unborn child

H373 - May cause damage to organs through prolonged or repeated exposure

H411 - Toxic to aquatic life with long lasting effects

## Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P273 - Avoid release to the environment

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P314 - Get medical advice/attention if you feel unwell

P391 - Collect spillage

P405 - Store locked up

P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

## Unknown acute toxicity

4-8 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.

4-8 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

## 2.3. Other hazards

### Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

### Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
---------------	----------	---------------------------	---------------------	--	------------------------------------	----------	----------------------

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 3 / 19

Version 6

				(EC) No. 1272/2008 [CLP]			
Methylprednisolone Acetate (CAS #: 53-36-1)	4-8		200-171-3	Repr.1A (H360D) STOT RE.2 (H373) Aquatic Acute 3 (H402) Aquatic Chronic 1 (H410)	Not classified	No data available	1
Myristyl-gamma-picoli nium chloride (CAS #: 2748-88-1)	<1.0		220-387-1	Acute Tox.3 (H301)	Not classified	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7 (017-002-00-2) (017-002-01-X)	Press. Gas Skin Corr. 1A (H314) Acute Tox. 3 (H331)	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

## NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Polyethylene glycol (CAS #: 25322-68-3)	*		Not Listed	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available
Sodium phosphate, monobasic (CAS #: 7558-80-7)	*		231-449-2	Not classified	Not classified	No data available	No data available
Sodium phosphate, dibasic (CAS #: 7558-79-4)	*		231-448-7	Not classified	Not classified	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 4 / 19

Version 6

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Methylprednisolone Acetate 53-36-1	10000	No data available	No data available	No data available	No data available
Polyethylene glycol 25322-68-3	22000	20000	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Sodium phosphate, monobasic 7558-80-7	8290	7940	0.83	No data available	No data available
Sodium phosphate, dibasic 7558-79-4	17000	No data available	No data available	No data available	No data available
Myristyl-gamma-picoliniu m chloride 2748-88-1	250	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

+ Substance with a Union workplace exposure limit

\* Proprietary

\*\* to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 5 / 19

Version 6

## Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

## 4.3. Indication of any immediate medical attention and special treatment needed

### Note to physicians

None.

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

#### Suitable Extinguishing Media

Dry chemical, CO2, alcohol-resistant foam or water spray.

### 5.2. Special hazards arising from the substance or mixture

#### Specific hazards arising from the chemical

Fine particles (such as mists) may fuel fires/explosions.

#### Hazardous combustion products

Formation of toxic gases is possible during heating or fire. May include oxides of carbon.

#### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 5.3. Advice for firefighters

#### Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

#### Personal precautions

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### For emergency responders

Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

#### Environmental precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

#### Methods for containment

Prevent further leakage or spillage if safe to do so.

#### Methods for cleaning up

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

#### Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

#### Reference to other sections

See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 6 / 19

Version 6

## 7.1. Precautions for safe handling

### Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

## 7.2. Conditions for safe storage, including any incompatibilities

### Storage Conditions

Store as directed by product packaging.

## 7.3. Specific end use(s)

### Specific use(s)

Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Methylprednisolone Acetate

Pfizer OEL TWA-8 Hr: 40 µg/m<sup>3</sup>

#### Polyethylene glycol

Austria

TWA-TMW: 1000 mg/m<sup>3</sup>; inhalable fraction

STEL-KZGW: 4000 mg/m<sup>3</sup> (4 X 15 min); inhalable fraction

Denmark

TWA: 1000 mg/m<sup>3</sup>;

STEL: 2000 mg/m<sup>3</sup>;

Germany DFG

TWA-MAK: 250 mg/m<sup>3</sup>; II(2);inhalable fraction

Peak: 500 mg/m<sup>3</sup>; inhalable fraction

Germany TRGS

TWA-AGW; 200 mg/m<sup>3</sup> (exposure factor 2); inhalable fraction

Russia

MAC: 10 mg/m<sup>3</sup>

Slovakia

TWA: 1000 mg/m<sup>3</sup>;

Switzerland

TWA-MAK: 500 mg/m<sup>3</sup>;

#### SODIUM CHLORIDE

Latvia

TWA: 5 mg/m<sup>3</sup>;

Russia

MAC: 5 mg/m<sup>3</sup>

#### Sodium phosphate, monobasic

Russia

MAC: 10 mg/m<sup>3</sup>

#### Sodium phosphate, dibasic

Russia

MAC: 10 mg/m<sup>3</sup>

#### Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m<sup>3</sup>

ACGIH TLV

Ceiling: 2 mg/m<sup>3</sup>

Austria

TWA-TMW: 2 mg/m<sup>3</sup>; inhalable fraction

STEL-KZGW: 4 mg/m<sup>3</sup> (8 X 5 min); inhalable fraction

Bulgaria

TWA: 2.0 mg/m<sup>3</sup>; alkaline aerosols

Czech Republic

1 mg/m<sup>3</sup>

Ceiling: 2 mg/m<sup>3</sup>

Denmark

Ceiling: 2 mg/m<sup>3</sup>;

Estonia

TWA: 1 mg/m<sup>3</sup>;

STEL: 2 mg/m<sup>3</sup>;

Finland

Ceiling: 2 mg/m<sup>3</sup>;

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 7 / 19

Version 6

France	2 mg/m <sup>3</sup>
Hungary	TWA-AK: 1 mg/m <sup>3</sup> ; STEL-CK: 2 mg/m <sup>3</sup> ;
Ireland	STEL: 2 mg/m <sup>3</sup> ;
Ceiling Limit Value	2 mg/m <sup>3</sup>
Latvia	TWA: 0.5 mg/m <sup>3</sup> ;
Poland	TWA-NDS: 0.5 mg/m <sup>3</sup> ; STEL-NDSch: 1 mg/m <sup>3</sup> ;
Romania	TWA: 1 mg/m <sup>3</sup> ;
Slovakia	STEL: 3 mg/m <sup>3</sup> ;
Spain	TWA: 2 mg/m <sup>3</sup> ;
Switzerland	STEL (VLA-EC): 2 mg/m <sup>3</sup> ;
OSHA PEL	TWA-MAK: 2 mg/m <sup>3</sup> ; inhalable dust STEL-KZGW: 2 mg/m <sup>3</sup> ; inhalable dust
United Kingdom	TWA: 2 mg/m <sup>3</sup> (vacated) Ceiling: 2 mg/m <sup>3</sup> STEL: 2 mg/m <sup>3</sup> ;
<b>+ Hydrochloric Acid</b>	
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	TWA-TMW: 5 ppm; TWA-TMW: 8 mg/m <sup>3</sup> ;
Bulgaria	STEL-KZGW: 10 ppm (8 X 5 min); STEL-KZGW: 15 mg/m <sup>3</sup> (8 X 5 min); TWA: 5 ppm; TWA: 8.0 mg/m <sup>3</sup> ;
Czech Republic	STEL: 10 ppm; STEL: 15.0 mg/m <sup>3</sup> ;
Denmark	8 mg/m <sup>3</sup> Ceiling: 15 mg/m <sup>3</sup>
Estonia	STEL: 5 ppm; STEL: 8 mg/m <sup>3</sup> ;
European Union	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ;
Finland	STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Germany DFG	STEL: 5 ppm; STEL: 7.6 mg/m <sup>3</sup> ;
Germany TRGS	TWA-MAK: 2 ppm; I(2); TWA-MAK: 3.0 mg/m <sup>3</sup> ; I(2); Peak: 4 ppm; Peak: 6 mg/m <sup>3</sup> ;
Hungary	TWA-AGW: 2 ppm (exposure factor 2); TWA-AGW: 3 mg/m <sup>3</sup> (exposure factor 2); TWA-AK: 8 mg/m <sup>3</sup> ;
Ireland	TWA-AK: 5 ppm; STEL-CK: 165 mg/m <sup>3</sup> ;
Italy MDLPS	STEL-CK: 10 ppm; TWA: 8 mg/m <sup>3</sup> ; TWA: 5 ppm; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ; TWA: 5 ppm;

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 8 / 19

Version 6

Ceiling Limit Value	TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ; 2 ppm 3.0 mg/m <sup>3</sup>
Latvia	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Netherlands	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Poland	TWA-NDS: 5 mg/m <sup>3</sup> ; STEL-NDSch: 10 mg/m <sup>3</sup> ;
Romania	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Russia	MAC: 5 mg/m <sup>3</sup>
Slovakia	TWA: 5 ppm; TWA: 8.0 mg/m <sup>3</sup> ; Ceiling: 15 mg/m <sup>3</sup> ;
Spain	TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m <sup>3</sup> ; STEL (VLA-EC): 10 ppm; STEL (VLA-EC): 15 mg/m <sup>3</sup> ;
Switzerland	TWA-MAK: 2 ppm; TWA-MAK: 3 mg/m <sup>3</sup> ; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m <sup>3</sup> ;
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m <sup>3</sup>
OSHA PEL	Ceiling: 5 ppm Ceiling: 7 mg/m <sup>3</sup> (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m <sup>3</sup>
United Kingdom	TWA: 1 ppm; gas and aerosol mist TWA: 2 mg/m <sup>3</sup> ; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m <sup>3</sup> ; gas and aerosol mist

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

### SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

### Sodium phosphate, monobasic

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

### Sodium phosphate, dibasic

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)



# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 9 / 19

Version 6

Band (OEB):

## Derived No Effect Level (DNEL) - Workers

Chemical name	Oral	Dermal	Inhalation
Polyethylene glycol 25322-68-3	-	112 mg/kg bw/day [4] [6]	40.2 mg/m <sup>3</sup> [4] [6]
SODIUM CHLORIDE 7647-14-5	-	295.52 mg/kg bw/day [4] [6] 295.52 mg/kg bw/day [4] [7]	2068.62 mg/m <sup>3</sup> [4] [6] 2068.62 mg/m <sup>3</sup> [4] [7]
+ Hydrochloric Acid 7647-01-0	-	-	8 mg/m <sup>3</sup> [5] [6] 15 mg/m <sup>3</sup> [5] [7]

## Derived No Effect Level (DNEL) - General Public

Chemical name	Oral	Dermal	Inhalation
Polyethylene glycol 25322-68-3	40 mg/kg bw/day [4] [6]	-	7.14 mg/m <sup>3</sup> [4] [6]
SODIUM CHLORIDE 7647-14-5	126.65 mg/kg bw/day [4] [6] 126.65 mg/kg bw/day [4] [7]	126.65 mg/kg bw/day [4] [6] 126.65 mg/kg bw/day [4] [7]	443.28 mg/m <sup>3</sup> [4] [6] 443.28 mg/m <sup>3</sup> [4] [7]
+ Hydrochloric Acid 7647-01-0	-	-	8 mg/m <sup>3</sup> [5] [6] 15 mg/m <sup>3</sup> [5] [7]

## Predicted No Effect Concentration (PNEC)

Chemical name	Freshwater	Freshwater (intermittent release)	Marine water	Marine water (intermittent release)	Air
Polyethylene glycol 25322-68-3	0.273 g/L	1 mg/L	27.3 mg/L	0.1 mg/L	-
SODIUM CHLORIDE 7647-14-5	5 mg/L	-	-	-	-
Sodium phosphate, monobasic 7558-80-7	0.05 mg/L	0.5 mg/L	0.005 mg/L	-	-
Sodium phosphate, dibasic 7558-79-4	0.05 mg/L	0.5 mg/L	0.005 mg/L	-	-

Chemical name	Freshwater sediment	Marine sediment	Sewage treatment	Soil	Food chain
Polyethylene glycol 25322-68-3	1030 mg/kg sediment dw	103 mg/kg sediment dw	-	46.4 mg/kg soil dw	-
SODIUM CHLORIDE 7647-14-5	-	-	500 mg/L	4.86 mg/kg soil dw	-
Sodium phosphate, monobasic 7558-80-7	-	-	50 mg/L	-	-
Sodium phosphate, dibasic 7558-79-4	-	-	50 mg/L	-	-

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 10 / 19

Version 6

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### Thermal hazards

No information available.

### Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

#### Appearance

suspension

#### Physical state

Liquid

#### Color

White

#### Odor

No information available.

#### Odor threshold

No information available

#### Property

#### Values

#### Melting point / freezing point

No data available

#### Boiling point or initial boiling point and boiling range

No data available

#### Flammability (solid, gas)

No data available

#### Lower and upper explosion limit/flammability limit

##### Lower explosion limit

No data available

##### Upper explosion limit

No data available

#### Flash point

No data available

#### Autoignition temperature

No data available

#### Decomposition temperature

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 11 / 19

Version 6

<b>SADT (°C)</b>	No data available
<b>pH</b>	3.5 to 7.0
<b>pH (as aqueous solution)</b>	No data available
<b>Kinematic viscosity</b>	No data available
<b>Dynamic viscosity</b>	No data available
<b>Solubility</b>	No data available
<b>Vapor pressure</b>	No data available
<b>Density and/or relative density</b>	No data available
<b>Bulk density</b>	No data available
<b>Liquid Density</b>	No data available
<b>Vapor density</b>	No data available
<b>Particle characteristics</b>	
<b>Particle Size</b>	No information available
<b>Particle Size Distribution</b>	No information available

## **Partition Coefficient: (Method, pH, Endpoint, Value)**

### **Myristyl-gamma-picolinium chloride**

Predicted 7.4 Log D 1.30

### **Methylprednisolone**

Predicted 7.4 Log D 1.99

## **9.2. Other information**

### **Molecular formula**

Mixture

### **Molecular weight**

Mixture

### **9.2.1. Information with regard to physical hazard classes**

No information available

### **9.2.2. Other safety characteristics**

No information available

## **Section 10: STABILITY AND REACTIVITY**

### **10.1. Reactivity**

**Reactivity** No information available.

### **10.2. Chemical stability**

**Stability** Stable under normal conditions.

### **Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### **10.3. Possibility of hazardous reactions**

**Possibility of hazardous reactions** No information available.

### **Hazardous polymerization**

Will not occur.

### **10.4. Conditions to avoid**

### **Conditions to avoid**

Fine particles (such as dust and mists) may fuel fires/explosions.

### **10.5. Incompatible materials**

### **Incompatible materials**

As a precautionary measure, keep away from strong oxidizers.

### **10.6. Hazardous decomposition products**

**Hazardous decomposition products** No data available.

## **Section 11: TOXICOLOGICAL INFORMATION**

### **11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008**

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 12 / 19

Version 6

## General Information:

The information included in this section describes the potential hazards of the individual ingredients. The information included in this section describes the potential hazards of various forms of the active ingredient.

## Short term

May be harmful if absorbed through the skin.

## Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on developing fetus and blood and blood forming organs.

## Known Clinical Effects:

Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations. Clinical use has resulted in changes in electrolytes and/or blood chemistry changes.

## Acute toxicity

Based on available data, the classification criteria are not met.

## Serious eye damage/eye irritation

Based on available data, the classification criteria are not met.

## Skin corrosion/irritation

Based on available data, the classification criteria are not met.

## Respiratory or skin sensitization

Based on available data, the classification criteria are not met.

## STOT - single exposure

Based on available data, the classification criteria are not met.

## STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure. Classification is based on mixture calculation methods based on component data.

## Reproductive toxicity

May damage the unborn child. Classification is based on mixture calculation methods based on component data.

## Germ cell mutagenicity

Based on available data, the classification criteria are not met.

## Carcinogenicity

Based on available data, the classification criteria are not met.

## Aspiration hazard

Based on available data, the classification criteria are not met.

## Acute Toxicity: (Species, Route, End Point, Dose)

### Methylprednisolone Acetate

Rat Oral LD50 >10,000 mg/kg

Mouse Sub-tenon injection (eye) LD50 >1,409 mg/kg

Rat Subcutaneous LD50 265 mg/kg

### SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

### Myristyl-gamma-picolinium chloride

Rat Oral LD 50 250 mg/kg

Rat Para-periosteal LD50 30 mg/kg

Rat Intraperitoneal LD50 7500 ug/kg

Rat Subcutaneous LD50 200 mg/kg

### Sodium hydroxide

Mouse IP LD50 40 mg/kg

### Methylprednisolone

Rat Oral LD 50 > 2000 mg/kg

Mouse Oral LD 50 450 mg/kg

Rat Intraperitoneal LD 50 1000 mg/kg

Mouse Intraperitoneal LD 50 1409 mg/kg

Rat Subcutaneous LD 50 >3000 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
Methylprednisolone Acetate	> 10 g/kg ( Rat )	-	-
Polyethylene glycol	= 22 g/kg ( Rat )	> 20 g/kg ( Rabbit )	-
SODIUM CHLORIDE	= 3550 mg/kg ( Rat )	> 10000 mg/kg ( Rabbit )	> 42 mg/L ( Rat ) 1 h

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 13 / 19

Version 6

Sodium phosphate, monobasic	= 8290 mg/kg ( Rat )	> 7940 mg/kg ( Rabbit )	> 0.83 mg/L ( Rat ) 4 h
Sodium phosphate, dibasic	= 17 g/kg ( Rat )	-	-
Myristyl-gamma-picolinium chloride	= 250 mg/kg ( Rat )	-	-
Sodium hydroxide	= 325 mg/kg ( Rat )	= 1350 mg/kg ( Rabbit )	-
+ Hydrochloric Acid	238 - 277 mg/kg ( Rat )	> 5010 mg/kg ( Rabbit )	= 1.68 mg/L ( Rat ) 1 h

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

## Unknown acute toxicity

4-8 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.

4-8 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

## Irritation / Sensitization: (Study Type, Species, Severity)

### Methylprednisolone Acetate

Eye Irritation Rabbit No effect

Skin Irritation Rabbit No effect

### Polyethylene glycol

Eye Irritation Rabbit Mild

Skin Irritation Rabbit Mild

### SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

### + Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

### Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

### Methylprednisolone

Skin irritation Rabbit No effect

Eye irritation Rabbit No effect

Skin Sensitization - GPMT Guinea Pig No effect

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

### Myristyl-gamma-picolinium chloride

60 Day(s) Rat Oral 2400 mg/kg Death

### Methylprednisolone

42 Day(s) Dog Oral 167 µg/kg/day LOAEL Adrenal gland

6 Week(s) Rat Subcutaneous 500 µg/kg/day LOAEL None identified

14 Week(s) Rat Subcutaneous 0.4 µg/kg/day NOAEL Blood forming organs, Adrenal gland

52 Week(s) Rat Subcutaneous 4 µg/kg/day NOAEL Blood forming organs, Adrenal gland

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Methylprednisolone

Reproductive & Fertility Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity

Reproductive & Fertility Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity

Embryo / Fetal Development Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic

Embryo / Fetal Development Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic

Embryo / Fetal Development Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 14 / 19

Version 6

## **Methylprednisolone Acetate**

Direct DNA Interaction Not applicable Negative  
*In Vitro* Cytogenetics Not applicable Negative

## **+ Hydrochloric Acid**

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
*In Vivo* Micronucleus Rat Negative

## **Methylprednisolone**

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
Unscheduled DNA Synthesis Rat Hepatocyte Negative  
Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative  
Direct DNA Interaction Negative

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## **+ Hydrochloric Acid**

IARC Group 3

## **11.2. Information on other hazards**

### **11.2.1. Endocrine disrupting properties**

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### **11.2.2. Other information**

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided. Toxic to aquatic life with long lasting effects. Classification is based on mixture calculation methods based on component data.

### **12.1. Toxicity**

#### **Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

##### **Methylprednisolone**

*Daphnia magna* (Water Flea) N/A EC50 48 hours > 85 mg/L  
*Daphnia magna* (Water Flea) N/A NOEC 48 hours 85 mg/L  
*Ceriodaphnia dubia* (Daphnids) N/A EC50 48 hours 19 mg/L  
*Ceriodaphnia dubia* (Daphnids) N/A EC10 48 hours 6.1 mg/L  
*Pseudokirchneriella subcapitata* (Green Alga) N/A NOEC 96 hours 160 mg/L

#### **Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)**

##### **Methylprednisolone**

*Ceriodaphnia dubia* (Daphnids) N/A 7 Day(s) EC50 0.23 mg/L  
*Ceriodaphnia dubia* (Daphnids) N/A 32 Day(s) EC10 0.031 mg/L Reproduction  
*Ceriodaphnia dubia* (Daphnids) N/A 32 Day(s) EC50 0.094 mg/L Reproduction

### **12.2. Persistence and degradability**

**Persistence and degradability** No information available.

### **12.3. Bioaccumulative potential**

**Bioaccumulation**

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 15 / 19

Version 6

## **Partition Coefficient: (Method, pH, Endpoint, Value)**

### **Myristyl-gamma-picolinium chloride**

Predicted 7.4 Log D 1.30

### **Methylprednisolone**

Predicted 7.4 Log D 1.99

## **12.4. Mobility in soil**

**Mobility in soil** No information available.

## **12.5. Results of PBT and vPvB assessment**

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Polyethylene glycol	Not PBT/vPvB
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Sodium phosphate, monobasic	PBT assessment does not apply
Sodium phosphate, dibasic	PBT assessment does not apply
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

## **12.6. Endocrine disrupting properties**

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## **12.7. Other adverse effects**

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## **Section 13: DISPOSAL CONSIDERATIONS**

### **13.1. Waste treatment methods**

#### **Waste from residues/unused products**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## **Section 14: TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

This material is regulated for transport as a hazardous material/dangerous good under IMDG, ADR, IATA but not under DOT.

**UN number:** UN 3077  
**UN proper shipping name:** Environmentally Hazardous Substance, Solid, n.o.s (Methylprednisolone Acetate)

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 16 / 19

Version 6

**Transport hazard class(es):** 9  
**Packing group:** III  
**Environmental Hazard(s):** Marine Pollutant

## 5 kg/5L Exception:

UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not subject to the dangerous goods transportation regulations by any mode:

\* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

\* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### Water

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-791-2
<b>AICS</b>	Present

#### Methylprednisolone Acetate

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	200-171-3

#### Polyethylene glycol

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	Not Listed
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 3 Schedule 2

#### SODIUM CHLORIDE

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-598-3
<b>AICS</b>	Present

#### Sodium phosphate, monobasic

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-449-2
<b>AICS</b>	Present

#### Sodium phosphate, dibasic

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-448-7
<b>AICS</b>	Present



# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 17 / 19

Version 6

<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6
Myristyl-gamma-picolinium chloride	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	220-387-1
<b>AICS</b>	Present
Sodium hydroxide	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	1000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	215-185-5
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6
+ Hydrochloric Acid	
<b>CERCLA/SARA Section 313 de minimus %</b>	1.0 %
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-595-7
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6

## National regulations

### France

#### Occupational Illnesses (R-463-3, France)

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

### Germany

#### Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

### Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable

**Storage of Hazardous Material** Not applicable

**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable

**Major Accidents Ordinance SR 814.012** Not applicable

### European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

#### Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide	75	-

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 18 / 19

Version 6

1310-73-2		
+ Hydrochloric Acid 7647-01-0	75	-

## Persistent Organic Pollutants

Not applicable

## Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid 7647-01-0	25	250

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

## EU - Plant Protection Products (1107/2009/EC)

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent

## Biocidal Products Regulation (EU) No 528/2012 (BPR)

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene
+ Hydrochloric Acid 7647-01-0	Product-type 2: Disinfectants and algaecides not intended for direct application to humans or animals

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

Chemical Safety Report No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H360D - May damage the unborn child. H373 - May cause damage to organs through prolonged or repeated exposure if

# SAFETY DATA SHEET

Product Name Methylprednisolone Acetate Injectable Suspension,  
Single-Dose Vial  
Revision date 15-Jun-2025

Page 19 / 19

Version 6

swallowed. H301 - Toxic if swallowed. H335 - May cause respiratory irritation. H314 - Causes severe skin burns and eye damage. H331 - Toxic if inhaled. H410 - Very toxic to aquatic life with long lasting effects. H402 - Harmful to aquatic life.

## Classification procedure

Calculation method

## Data Sources:

Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.

## Reason for revision

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

## Revision date

15-Jun-2025

## Prepared By

Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**